First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Subscribe To Our Newsletter & Stay Updated
